Question 1

Does Price T Rowe Associates own MLTX stock?

Accepted Answer

Yes. As of its Q2 2026 13F, Price T Rowe Associates holds 1,041,527 shares of MLTX (Moonlake Immunotherapeutics), worth $20.3M.

Question 2

How many shares of MLTX does Price T Rowe Associates own?

Accepted Answer

As of its Q2 2026 13F, Price T Rowe Associates holds 1,041,527 shares of MLTX (Moonlake Immunotherapeutics).

Question 3

What is Price T Rowe Associates' MLTX position worth?

Accepted Answer

As of its Q2 2026 13F, Price T Rowe Associates' MLTX position is worth $20.3M.

Question 4

Is Price T Rowe Associates buying or selling MLTX?

Accepted Answer

In Q2 2026, Price T Rowe Associates reduced its MLTX position by 253,334 shares (-19.6%).

Question 5

When did Price T Rowe Associates first buy MLTX?

Accepted Answer

Price T Rowe Associates first reported MLTX in its Q2 2022 13F and has listed it in 17 quarterly 13F filings.

Quarter	Action	Shares	Change	Value	Weight	Price	Conviction
2026-Q2 Latest	Decreased	1M	-19.6%	$20.3M	0.0%	$19.47	0
2026-Q1	Increased	1.3M	+34.9%	$24.1M	0.0%	$17.69	37
2025-Q4	Increased	959,553	+16.6%	$12.6M	0.0%	$13.21	32
2025-Q3	Decreased	822,957	-68.5%	$5.9M	0.0%	$6.24	0
2025-Q2	Decreased	2.6M	-12.1%	$123.3M	0.0%	$47.52	0
2025-Q1	Decreased	3M	-11.1%	$116.2M	0.0%	$39.86	0
2024-Q4	Increased	3.3M	+12.2%	$181.1M	0.0%	$53.02	34
2024-Q3	Increased	3M	+16.4%	$150.3M	0.0%	$49.40	35